HomeCompareVRCDF vs DIVO

VRCDF vs DIVO: Dividend Comparison 2026

VRCDF yields 66666.67% · DIVO yields 6.49%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VRCDF wins by $8.441837856534449e+24M in total portfolio value
10 years
VRCDF
VRCDF
● Live price
66666.67%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.441837856534449e+24M
Annual income
$8,417,001,582,403,749,000,000,000,000,000.00
Full VRCDF calculator →
DIVO
DIVO
● Live price
6.49%
Share price
$44.85
Annual div
$2.91
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$981.68
Full DIVO calculator →

Portfolio growth — VRCDF vs DIVO

📍 VRCDF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVRCDFDIVO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VRCDF + DIVO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VRCDF pays
DIVO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VRCDF
Annual income on $10K today (after 15% tax)
$5,666,666.67/yr
After 10yr DRIP, annual income (after tax)
$7,154,451,345,043,187,000,000,000,000,000.00/yr
DIVO
Annual income on $10K today (after 15% tax)
$552.00/yr
After 10yr DRIP, annual income (after tax)
$834.43/yr
At 15% tax rate, VRCDF beats the other by $7,154,451,345,043,187,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VRCDF + DIVO for your $10,000?

VRCDF: 50%DIVO: 50%
100% DIVO50/50100% VRCDF
Portfolio after 10yr
$4.2209189282672247e+24M
Annual income
$4,208,500,791,201,874,400,000,000,000,000.00/yr
Blended yield
99.71%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VRCDF buys
0
DIVO buys
0
No recent congressional trades found for VRCDF or DIVO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVRCDFDIVO
Forward yield66666.67%6.49%
Annual dividend / share$2.00$2.91
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$8.441837856534449e+24M$30.7K
Annual income after 10y$8,417,001,582,403,749,000,000,000,000,000.00$981.68
Total dividends collected$8.44020886744369e+24M$8.2K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: VRCDF vs DIVO ($10,000, DRIP)

YearVRCDF PortfolioVRCDF Income/yrDIVO PortfolioDIVO Income/yrGap
1← crossover$6,677,367$6,666,666.67$11,349$649.42+$6.67MVRCDF
2$4,167,497,846$4,160,353,063.34$12,833$688.83+$4167.49MVRCDF
3$2,431,161,901,635$2,426,702,678,939.67$14,459$727.90+$2431161.89MVRCDF
4$1,325,636,209,022,888$1,323,034,865,788,139.00$16,238$766.49+$1325636209.01MVRCDF
5$675,632,775,263,916,700$674,214,344,520,262,300.00$18,179$804.47+$675632775263.90MVRCDF
6$321,867,481,182,444,260,000$321,144,554,112,911,900,000.00$20,293$841.71+$321867481182444.25MVRCDF
7$143,326,993,661,751,470,000,000$142,982,595,456,886,240,000,000.00$22,591$878.14+$143326993661751472.00MVRCDF
8$59,657,925,421,851,500,000,000,000$59,504,565,538,633,426,000,000,000.00$25,087$913.65+$59657925421851500544.00MVRCDF
9$23,211,471,150,187,795,000,000,000,000$23,147,637,169,986,416,000,000,000,000.00$27,791$948.18+$2.3211471150187796e+22MVRCDF
10$8,441,837,856,534,450,000,000,000,000,000$8,417,001,582,403,749,000,000,000,000,000.00$30,718$981.68+$8.441837856534449e+24MVRCDF

VRCDF vs DIVO: Complete Analysis 2026

VRCDFStock

Verici Dx plc, an immuno-diagnostics development company, focuses on the kidney transplantation market. The company develops prognostic and diagnostic tests for kidney transplant patients. Its in-development tests include Clarava, a pre-transplant prognosis test for the risk of early acute rejection; Tuteva, a post-transplant test that focuses on acute cellular rejection; and Protega, a liquid biopsy that aims to predict the risk of fibrosis and long-term graft failure. The company was incorporated in 2020 and is based in Penarth, the United Kingdom.

Full VRCDF Calculator →

DIVOETF

DIVO is an ETF of high-quality large cap companies with a history of dividend and earnings growth, along with a tactical covered call* strategy on individual stocks. DIVO is strategically designed to offer high levels of total return on a risk-adjusted basis.

Full DIVO Calculator →
📬

Get this VRCDF vs DIVO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VRCDF vs SCHDVRCDF vs JEPIVRCDF vs OVRCDF vs KOVRCDF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.